DNLI
Price
$16.25
Change
+$0.57 (+3.64%)
Updated
Apr 28 closing price
Capitalization
2.36B
14 days until earnings call
LGND
Price
$108.88
Change
+$0.81 (+0.75%)
Updated
Apr 28 closing price
Capitalization
2.1B
9 days until earnings call
Ad is loading...

DNLI vs LGND

Header iconDNLI vs LGND Comparison
Open Charts DNLI vs LGNDBanner chart's image
Denali Therapeutics
Price$16.25
Change+$0.57 (+3.64%)
Volume$1.42M
Capitalization2.36B
Ligand Pharmaceuticals
Price$108.88
Change+$0.81 (+0.75%)
Volume$84.56K
Capitalization2.1B
DNLI vs LGND Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. LGND commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and LGND is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (DNLI: $16.25 vs. LGND: $108.88)
Brand notoriety: DNLI and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 94% vs. LGND: 67%
Market capitalization -- DNLI: $2.36B vs. LGND: $2.1B
DNLI [@Biotechnology] is valued at $2.36B. LGND’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $272.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while LGND’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • LGND’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, LGND is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +23.57% price change this week, while LGND (@Biotechnology) price change was +3.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.96%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -9.88%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

LGND is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.36B) has a higher market cap than LGND($2.1B). LGND YTD gains are higher at: 1.615 vs. DNLI (-20.265). LGND has higher annual earnings (EBITDA): 40.8M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. LGND (256M). LGND has less debt than DNLI: LGND (7.11M) vs DNLI (48.7M). LGND has higher revenues than DNLI: LGND (167M) vs DNLI (0).
DNLILGNDDNLI / LGND
Capitalization2.36B2.1B112%
EBITDA-492.89M40.8M-1,208%
Gain YTD-20.2651.615-1,255%
P/E RatioN/A46.19-
Revenue0167M-
Total Cash832M256M325%
Total Debt48.7M7.11M685%
FUNDAMENTALS RATINGS
DNLI vs LGND: Fundamental Ratings
DNLI
LGND
OUTLOOK RATING
1..100
2213
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
9847
SMR RATING
1..100
3990
PRICE GROWTH RATING
1..100
6047
P/E GROWTH RATING
1..100
9890
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LGND's Valuation (77) in the Biotechnology industry is in the same range as DNLI (94). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for DNLI (98). This means that LGND’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for LGND (90). This means that DNLI’s stock grew somewhat faster than LGND’s over the last 12 months.

LGND's Price Growth Rating (47) in the Biotechnology industry is in the same range as DNLI (60). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's P/E Growth Rating (90) in the Biotechnology industry is in the same range as DNLI (98). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLILGND
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
60%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 15 days ago
74%
Declines
ODDS (%)
Bearish Trend 14 days ago
80%
Bearish Trend 22 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
73%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNWAX75.530.20
+0.27%
American Funds New World R1
GSIFX29.01N/A
N/A
Goldman Sachs International Eq ESG A
LRSFX13.38N/A
N/A
Lord Abbett Small Cap Value F
PRUAX15.06N/A
N/A
PGIM Jennison Utility A
JVSAX13.41N/A
N/A
Janus Henderson Small-Mid Cap Value A

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
+0.75%
AXON - LGND
49%
Loosely correlated
-0.22%
ACLX - LGND
49%
Loosely correlated
+1.32%
CRNX - LGND
47%
Loosely correlated
+2.22%
DNLI - LGND
45%
Loosely correlated
+3.64%
ROIV - LGND
45%
Loosely correlated
+1.63%
More